Project Grant W81XWH2010422

This $8,042,749 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding research at The Ohio State University to enhance the safety and efficacy of low-titer Group O whole blood. The research involves determining optimal concentrations of hemopexin, haptoglobin, and transferrin to neutralize hemolytic byproducts during ex vivo storage of whole blood units. The project includes testing this protein...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a $1.748 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop intravenous oxygen (IVO2) therapy for treating cardiac arrest. The grant, awarded May 21, 2025, with completion targeted for March 31, 2029, supports research on pH-responsive polymeric microbubbles (PMBs)—oxygen-carrying particles with polymer shells approximately...

Federal Grant Award Summary The Ohio State University received a $784,227 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for April 30, 2029. The award funds research to engineer hemoglobin-based oxygen carriers (HBOCs) for use as oxygen-carrying perfusates in normothermic ex vivo lung perfusion (EVLP) systems. The primary deliverable is the development and...

Federal Grant Award Summary Pranions, Inc. received a $2.43 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with completion targeted for July 31, 2027. The company is developing a next-generation, high-flow portable oxygen concentrator (POC) designed to address critical limitations in existing commercial devices for the 1.5 million Americans requiring long-term oxygen...

Federal Project Grant Award Summary New Health Sciences, Inc. (doing business as Hemanext Inc.) received a $1,017,232 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 5, 2025, with completion scheduled for August 31, 2028. The award supports a rigorous clinical efficacy trial evaluating hypoxic red blood cell (HRBC) transfusions processed using the HemaNEXT ONE System compared to...

The Regents of the University of California, San Francisco will use a $323,000 Project Grant from the Department of the Army Medical Command to support research titled "PUMPLESS AND ANTICOAGULATION-FREE EXTRACORPOREAL MEMBRANE OXYGENATION" from September 1, 2022 to August 31, 2024. The research is being conducted under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research...

Federal Project Grant Award Summary Haima Therapeutics LLC received a $944,676 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 15, 2025, with a completion date of June 30, 2027. The award supports the development and advancement of Synthoplate (SP), a platelet-inspired synthetic hemostatic nanoparticle designed to restore hemostatic function in traumatic brain injury (TBI) patients...

This $256,000 National Science Foundation SBIR Phase I Project Grant to Airomatix, Inc. supports the development of a portable oxygen concentrator capable of producing breathable oxygen at higher flow rates than current models. The concentrator utilizes a novel photocatalytic reaction to separate oxygen from ambient air and store it in a chemical solution. It will then release oxygen on demand through a temperature-controlled reaction. During the one-year period of performance ending March 2023,...

Federal Grant Award Summary Award Overview Resuscitation Innovations LLC (doing business as Advanced CPR Solutions LLC) received a $498,453 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025, through August 31, 2026. The award supports the commercialization of the ELEGARD system, a novel Head Up Position (HUP) CPR device designed to improve neurologically-intact survival rates for...

Federal Project Grant Award Summary Limax Biosciences Inc. received a $464,229 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate HEMOMAX, a biodegradable hydrogel adhesive sealant for vascular surgery. The award, obligated on August 20, 2025, with completion targeted for July 31, 2026, supports a Phase I effort to advance the product toward FDA approval and commercial viability. The...